Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. - Wikidata - awgldk - TriplyDB

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

http://www.wikidata.org/entity/Q37400568

about

Targeted Therapies in Adult B-Cell Malignancies Profile of atacicept and its potential in the treatment of systemic lupus erythematosus Many multiple myelomas: making more of the molecular mayhem Molecular pathogenesis of multiple myeloma: basic and clinical updates Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma Development of Novel Immunotherapies for Multiple Myeloma Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.A critical role for the NFkB pathway in multiple myeloma.Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.New Therapeutic Approaches for Waldenstrom Macroglobulinemia Antibody-based therapies in multiple myeloma Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Molecular pathogenesis of multiple myeloma and its premalignant precursor.Clinical targeting of the TNF and TNFR superfamilies APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.The kinase NIK as a therapeutic target in multiple myeloma.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Atacicept as an investigated therapy for rheumatoid arthritis.B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?Targeting B-cell maturation antigen in multiple myeloma.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.Positioning NK-kappaB in multiple myeloma.Emerging immune targets for the treatment of multiple myeloma.

P2860

Q26783195-20898519-7B9D-42CA-B0D6-8D1D90552B2C Q26849719-6F188494-F7AF-40FF-8F38-5C06F77B23BC Q26852892-73C8568A-E762-4E23-91DD-E7F9EA5FAE38 Q27026205-E0D30E51-A176-497A-836E-FEC96CCA49F8 Q27700745-FBFDD719-1A7E-42C8-B96D-7203027EB6AC Q28066890-8A626A6E-5BD2-45C3-8ED5-3315858DA5B4 Q28291793-CE255CFD-678A-4547-881E-8D35C9334C62 Q33417346-6AC88129-6513-4D79-AEC0-5644B5C77D77 Q33564854-8BDC2954-C487-4D80-B97E-ADF4446B4FF5 Q33889168-97265F52-6A35-4206-B067-1243AE81D39E Q34101051-7EA89AEC-78DA-4AA7-80E7-1C3613D14463 Q34165181-F41D80B7-4016-414D-8E32-26E16F48E07F Q34263870-9A6A184C-C270-468A-BCE7-D854CFE723E9 Q35176177-20304AE6-34F7-4F1C-9566-A760DE0B4552 Q35431150-18EB22C6-5B30-4A5C-82CA-5CEE83F6BAAB Q35584599-6A265149-5221-4655-BE6B-7E30EE2EBF6E Q36290238-8221DCB1-939E-4460-9FDA-1D4AE00B4C10 Q36762882-860E3769-2FAF-42F3-BB55-5F3B9EF7477F Q37035836-1EEF554E-4A79-4FC3-8D89-A274D5C18843 Q37054982-68EAB755-FC08-4E69-9268-1AA450BA06EB Q37622417-3BC1CBDA-4448-4A13-A86E-C4303902B1D3 Q37825898-5CECC1E1-7C51-4FFF-86C9-1F90678C26BA Q38090691-12C62488-06C6-4070-A1FE-742F6F9A8A58 Q38235570-1419608A-0AB8-4CAE-9B27-EE8FE27CA8CA Q38365867-EC03E119-B895-4CDB-A6C6-C4FB1F5EC1BD Q38586922-FAE607DA-2136-40D0-A1AF-07FE278AF080 Q38601582-D551EC8C-EDB8-4366-866B-19778C4DEA59 Q38961202-FFC15C2D-949B-4871-95E2-442D5C8F10C5 Q41168768-9049FF96-4EBA-4EB8-95E0-0859A0EE5AAC Q41190031-03685FC4-8B33-4D7A-AC03-5E906954BA54 Q50025144-8E8CF68B-BE88-4674-B9CA-19D9424549F0

P2860

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

http://www.wikidata.org/entity/Q37400568

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@en

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@nl

type

label

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@en

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@nl

prefLabel

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@en

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@nl

P1433

Q37400568-17183E3F-2AD0-48E3-9725-1E62BE310876

P1476

Q37400568-A534F06C-670B-4C62-9A1D-3C5A8764ED5B

P2093

Q37400568-0E6F4675-254A-4912-BFCE-A787BF6F2E3D

Q37400568-19F4A17B-2A5E-4108-8F0B-1F34DDF2B872

Q37400568-1C471A3C-B1B3-466F-9A25-8F7C933FBFDE

Q37400568-32DCAB42-ADF5-4224-98AE-856BCDDB8A54

Q37400568-5CC1F9AB-5B02-4B4D-AEBE-76514BD9EDBB

Q37400568-5F1033A3-61B1-46AA-9268-44DF1D905D04

Q37400568-7E2154C1-25F1-4F3C-898C-B8CCF4DC39F5

Q37400568-B11C78BE-9C2D-4E0D-AD2F-6BD7FF00418B

Q37400568-C559E64F-3E11-4DAF-83EB-323F8B335DCB

Q37400568-CE411E44-3193-480E-9685-E091798A9C79

P2860

Q37400568-00F4BD79-E614-4FD5-91A8-52B6C44481FB

Q37400568-02D25B84-AE7C-4E3F-8B3A-41136B0DD935

Q37400568-1D7ACBAB-1F62-40C1-BA1B-6119C08DE041

Q37400568-1E885678-3946-4FA5-B6F1-E26D4A96BC7D

Q37400568-1ECBE2C9-86D8-42C7-8CAC-7AB7F2B9E587

Q37400568-2785278E-27A9-4970-B4BB-8673A30F8A77

Q37400568-27A68DC7-7E25-488C-AB58-772B359ACCA6

Q37400568-2F443A60-F9DD-4E03-B67E-FD6970243FAC

Q37400568-37EA819E-D16D-404D-8D47-581D6EF38237

Q37400568-3D51C05B-B7EF-4270-B246-51CA94F43FB6

P2888

Q37400568-3F23DEEA-70B3-4FCF-AE04-CA536BED268F

P304

Q37400568-2715C12D-E450-4C7F-BF50-49D0B30AC7CE

P31

Q37400568-6C50A150-F508-47D5-BDD7-66588D0EADB2

P356

Q37400568-E6AB95A3-5229-4703-A8D1-0F7B91240150

P407

Q37400568-FF7843A2-9CC6-4506-83BB-D76D66726583

P433

Q37400568-762BF124-F6A0-4965-9439-9EFABF430300

P478

Q37400568-BFBD455C-BB93-44DF-B8E8-CFE6D09F379A

P577

Q37400568-E400A89A-BA5D-4933-803A-D9ADBF38E6E4

P5875

Q37400568-51C2ABCF-CC4A-460F-9485-8F056BE93BE5

P6179

Q37400568-67AF62AC-962D-4F8C-95D8-AE59C43C41C5

P698

Q37400568-83F0BB29-79AB-48DB-AAD1-DA7B273E43FC

P932

Q37400568-F64EC027-18A7-4DCA-BCD1-1050A6782442

P356

P1433

British Journal of Cancer

P1476

Atacicept in relapsed/refracto ...... globulinemia: a phase I study.

@en

P2093

A Ythier

http://www.w3.org/2001/XMLSchema#string

B Klein

http://www.w3.org/2001/XMLSchema#string

D Hose

http://www.w3.org/2001/XMLSchema#string

G Mordenti

http://www.w3.org/2001/XMLSchema#string

G Requirand

http://www.w3.org/2001/XMLSchema#string

H Goldschmidt

http://www.w3.org/2001/XMLSchema#string

I Nestorov

http://www.w3.org/2001/XMLSchema#string

J Moreaux

http://www.w3.org/2001/XMLSchema#string

J-F Rossi

http://www.w3.org/2001/XMLSchema#string

M Rose

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

BCMA is essential for the survival of long-lived bone marrow plasma cells

Activation molecules on human myeloma cells.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Waldenström's macroglobulinemia: clinical features, complications, and management.

P2888

P304

1051-1058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605241

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26856337

http://www.w3.org/2001/XMLSchema#string

P6179

1048929076

http://www.w3.org/2001/XMLSchema#string

P698

19789533

http://www.w3.org/2001/XMLSchema#string

P932

2768101

http://www.w3.org/2001/XMLSchema#string